These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 36622205)
1. Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference. Graninger M; Jani CM; Reuberger E; Prüger K; Gaspar P; Springer DN; Borsodi C; Weidner L; Rabady S; Puchhammer-Stöckl E; Jungbauer C; Höltl E; Aberle JH; Stiasny K; Weseslindtner L Microbiol Spectr; 2023 Feb; 11(1):e0231422. PubMed ID: 36622205 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies. Zedan HT; Yassine HM; Al-Sadeq DW; Liu N; Qotba H; Nicolai E; Pieri M; Bernardini S; Abu-Raddad LJ; Nasrallah GK Sci Rep; 2022 Nov; 12(1):19020. PubMed ID: 36347859 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test. Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695 [TBL] [Abstract][Full Text] [Related]
4. Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273. Krüttgen A; Lauen M; Klingel H; Imöhl M; Kleines M J Virol Methods; 2022 Jan; 299():114297. PubMed ID: 34563583 [TBL] [Abstract][Full Text] [Related]
5. Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts. Adams O; Andrée M; Hermsen D; Lübke N; Timm J; Schaal H; Müller L J Virol Methods; 2022 Sep; 307():114569. PubMed ID: 35724697 [TBL] [Abstract][Full Text] [Related]
7. Performance evaluation of four surrogate Virus Neutralization Tests (sVNTs) in comparison to the Pieri M; Infantino M; Manfredi M; Nuccetelli M; Grossi V; Lari B; Tomassetti F; Sarubbi S; Russo E; Amedei A; Benucci M; Casprini P; Stacchini L; Castilletti C; Bernardini S Front Biosci (Landmark Ed); 2022 Feb; 27(2):74. PubMed ID: 35227017 [TBL] [Abstract][Full Text] [Related]
8. Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects. Cristiano A; Nuccetelli M; Pieri M; Sarubbi S; Pelagalli M; Calugi G; Tomassetti F; Bernardini S Int Immunopharmacol; 2021 Dec; 101(Pt B):108215. PubMed ID: 34649115 [TBL] [Abstract][Full Text] [Related]
10. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay. Resman Rus K; Korva M; Knap N; Avšič Županc T; Poljak M J Clin Virol; 2021 Jun; 139():104820. PubMed ID: 33865031 [TBL] [Abstract][Full Text] [Related]
11. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays. Valdivia A; Torres I; Latorre V; Francés-Gómez C; Albert E; Gozalbo-Rovira R; Alcaraz MJ; Buesa J; Rodríguez-Díaz J; Geller R; Navarro D Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):485-494. PubMed ID: 33404891 [TBL] [Abstract][Full Text] [Related]
12. Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers. Patel EU; Bloch EM; Clarke W; Hsieh YH; Boon D; Eby Y; Fernandez RE; Baker OR; Keruly M; Kirby CS; Klock E; Littlefield K; Miller J; Schmidt HA; Sullivan P; Piwowar-Manning E; Shrestha R; Redd AD; Rothman RE; Sullivan D; Shoham S; Casadevall A; Quinn TC; Pekosz A; Tobian AAR; Laeyendecker O J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139419 [TBL] [Abstract][Full Text] [Related]